GLP1R and obesity due to melanocortin 4 receptor deficiency: In the mesolimbic system, GLP-1R activation has been shown to attenuate the rewarding effects of palatable food and addictive substances, indicating potential therapeutic applications for GLP-1R agonists in treating obesity and SUDs [19,20,21].